Green SM has officially launched its all-electric taxi service in Los Angeles, marking its first entry into the U.S. market and ninth globally. The service features a 100% electric fleet of VinFast vehicles, professional drivers, and transparent pricing, aiming to provide a greener, comfortable, and reliable ride experience. To attract new customers, Green SM offers significant discounts and a membership with fare vouchers. This launch is part of Green SM's broader international expansion and commitment to sustainable mobility, with plans to grow its local team and contribute to greener transportation in the region.
Green SM's launch of an all-electric taxi service in the U.S. offers context for consumer cyclical stocks. For readers following this sector, here is Pluang's market snapshot as of Oct 14, 2026 23:21 WIB: out of 134 priced US consumer cyclical stocks, 26 rose and 108 fell. Notable movers include CPNG at USD 14.43 with a -4.56% change, LCID at USD 3.21 with a -4.47% change, and LI at USD 11.23 with a -4.43% change.
Jefferies has maintained a Buy rating on Big Yellow Group despite recent stock declines, citing the company's strong fundamentals including freehold properties and solid cash flows. Activist investor Ancora, holding over 4% of shares, is pushing Big ...
Fastenal reported strong Q3 2026 earnings, beating analyst expectations with EPS of $0.35 and revenue of $2.46 billion. The company saw a 20% rise in net income to $401.6 million and a 15.5% increase in revenue driven by robust manufacturing demand, ...
Remittix announced the public launch of its RTX token on November 24, 2026, marking the end of its presale phase which raised over $32 million from 40,000 participants. The project is testing its PayFi platform, which enables crypto-to-fiat and fiat-...
The global microbiology testing market is projected to grow rapidly at a compound annual growth rate (CAGR) of approximately 9% from 2026 to 2034, reaching a market size of $13.7 billion by 2034. This growth is driven by the rising prevalence of infe...
H.C. Wainwright raised its price target for Alector from $5.00 to $8.00, maintaining a Buy rating due to progress in its neurodegenerative disease pipeline. Alector develops treatments for Alzheimer's and Parkinson's using its Brain Carrier platform ...
